A BCNU-containing Regimen, Mini-BEAM, with GM-CSF is a Safe and Effective Mobilizing Regimen Pre-stem Cell Transplantation in Lymphoma Patients

References

• Nademanee, A., Sniecinski, I., Schmidt, G. M., Dagis, A. C. et al. (1994). High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells, Journal of Clinical Oncology, 12, 2176–2186.
   PubMed Web of Science ®Google Scholar
• Reece, D. E., Connors, J. M., Spinelli, J. J., Barnett, M. J. et al. (1994). Intensive therapy with cyclophosphamide, carmustine, etoposide cisplatin and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood, 83, 1193–1199.
   PubMed Web of Science ®Google Scholar
• Brice, P., Marolleau, J. P., Dombret, H., Lepage, E. et al. (1992). Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas. Bone Marrow Transplantation, 9, 337–342.
   PubMed Web of Science ®Google Scholar
• Chopra, R., Linch, D. C., McMillan, A. K., Blair, S. et al. (1992). Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. British Journal of Haematology, 81, 197–202.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh, M. G., Rueffer, U., Lathan, B., Schmitz, N. et al. (1994). Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group, Journal of Clinical Oncology, 12, 580–586.
   PubMed Web of Science ®Google Scholar
• Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R. et al. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [see comments]. New England Journal of Medicine, 333, 1540–1545.
   PubMed Web of Science ®Google Scholar
• Ahmed, T., Lake, D. E., Beer, M., Feldman, E. J. et al. (1997). Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone Marrow Transplantation, 19, 449–454.
   PubMed Web of Science ®Google Scholar
• Colwill, R., Crump, M., Couture, F., Danish, R. et al. (1995). Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation, Journal of Clinical Oncology, 13, 396–402.
   PubMed Web of Science ®Google Scholar
• Knauf, W. U., Koenigsmann, M. P., Notter, M., Hopp, B. et al. (1996). Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. Leukemia & Lymphoma, 23, 305–311.
   PubMed Web of Science ®Google Scholar
• Shpall, E. J., Jones, R. B., Bearman, S. I., Franklin, W. A. et al. (1994). Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. Journal of Clinical Oncology, 12, 28–36.
   PubMed Web of Science ®Google Scholar
• Beyer, J., Schwella, N., Zingsem, J., Strohscheer, I. et al. (1995). Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. Journal of Clinical Oncology, 13, 1328–1335.
   PubMed Web of Science ®Google Scholar
• Faucher, C., Le Corroller, A. G., Blaise, D., Novakovitch, G. et al. (1994). Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and costeffectiveness. Bone Marrow Transplantation, 14, 895–901.
   PubMed Web of Science ®Google Scholar
• Liberti, G., Pearce, R., Taghipour, G., Majolino, I. et al. (1994). Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT. Annals of Oncology, 5(Suppl 2), 151–153.
   PubMed Web of Science ®Google Scholar
• Mariette, X., Fermand, J. P., Brouet, J. C. (1994). Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplantation, 14, 47–50.
   PubMed Web of Science ®Google Scholar
• Botnick, L. E., Hannon, E. C. and Hellman, S. (1976). Limited proliferation of stem cells surviving alkylating agents. Nature, 262, 68–70.
   PubMed Web of Science ®Google Scholar
• Lohrmann, H. P., Lepp, K. A. and Schreml, W. (1982). 5-Fluorouracil, 1,3-bis(2-chloroethyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea: effect on the human granulopoietic system. Journal of the National Cancer Institute, 68, 541–547.
   PubMedGoogle Scholar
• Gribben, J. G., Goldstone, A. H., Linch, D. C., Taghipour, G. et al. (1989). Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy, Journal of Clinical Oncology, 7, 1621–1629.
   PubMed Web of Science ®Google Scholar
• Trainor, K. J., Seshadri, R. S. and Morley, A. A. (1979). Residual marrow injury following cytotoxic drugs. Leukemia Research, 3, 205–210.
   PubMed Web of Science ®Google Scholar
• Trainor, K. J. and Morley, A. A. (1976). Screening of cytotoxic drugs of residual bone marrow damage. Journal of the National Cancer Instiitute, 57, 1237–1239.
   PubMedGoogle Scholar
• Dreger, P., Marquardt, P., Haferlach, T., Jacobs, S. et al. (1993). Effective mobilization of peripheral blood progenitor cells with ‘Dexa-BEAM’ and G-CSF: timing of harvesting and composition of the leukapheresis product. British Journal of Cancer, 68, 950–957.
   PubMed Web of Science ®Google Scholar
• Dreger, P., Kloss, M., Petersen, B., Haferlach, T. et al. (1995). Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of pheripheral blood progenitor cells but not of bone marrow grafts. Blood, 86, 3970–3978.
   PubMed Web of Science ®Google Scholar
• Morton, J., Morton, A., Bird, R., Hutchins, C. et al. (1997). Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediated dose cyclophosphamide and G-CSF. Leukemia Research, 21, 21–27.
   PubMed Web of Science ®Google Scholar
• Bolwell, B. J., Fishleder, A., Andresen, S. W., Lichtin, A. E. et al. (1993). G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplantation, 12, 609–614.
   PubMed Web of Science ®Google Scholar
• Schmitz, N., Linch, D. C., Dreger, P., Goldstone, A. H. et al. (1996). Randomized trial of figrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet, 347, 353–357.
   PubMed Web of Science ®Google Scholar